These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23053736)

  • 21. Drug Analogs from Fragment-Based Long Short-Term Memory Generative Neural Networks.
    Awale M; Sirockin F; Stiefl N; Reymond JL
    J Chem Inf Model; 2019 Apr; 59(4):1347-1356. PubMed ID: 30908913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational combinatorial ligand design: application to human alpha-thrombin.
    Caflisch A
    J Comput Aided Mol Des; 1996 Oct; 10(5):372-96. PubMed ID: 8951649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DOGS: reaction-driven de novo design of bioactive compounds.
    Hartenfeller M; Zettl H; Walter M; Rupp M; Reisen F; Proschak E; Weggen S; Stark H; Schneider G
    PLoS Comput Biol; 2012; 8(2):e1002380. PubMed ID: 22359493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular modeling on pyruvate phosphate dikinase of Entamoeba histolytica and in silico virtual screening for novel inhibitors.
    Stephen P; Vijayan R; Bhat A; Subbarao N; Bamezai RN
    J Comput Aided Mol Des; 2008 Sep; 22(9):647-60. PubMed ID: 17710553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GroupBuild: a fragment-based method for de novo drug design.
    Rotstein SH; Murcko MA
    J Med Chem; 1993 Jun; 36(12):1700-10. PubMed ID: 8510098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De novo drug design.
    Hartenfeller M; Schneider G
    Methods Mol Biol; 2011; 672():299-323. PubMed ID: 20838974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SYNOPSIS: SYNthesize and OPtimize System in Silico.
    Vinkers HM; de Jonge MR; Daeyaert FF; Heeres J; Koymans LM; van Lenthe JH; Lewi PJ; Timmerman H; Van Aken K; Janssen PA
    J Med Chem; 2003 Jun; 46(13):2765-73. PubMed ID: 12801239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational quantum chemistry and adaptive ligand modeling in mechanistic QSAR.
    De Benedetti PG; Fanelli F
    Drug Discov Today; 2010 Oct; 15(19-20):859-66. PubMed ID: 20709183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Silico Laboratory: Tools for Similarity-Based Drug Discovery.
    Lešnik S; Konc J
    Methods Mol Biol; 2020; 2089():1-28. PubMed ID: 31773644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioisosteric similarity of molecules based on structural alignment and observed chemical replacements in drugs.
    Krier M; Hutter MC
    J Chem Inf Model; 2009 May; 49(5):1280-97. PubMed ID: 19402687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel indolizine derivatives with unprecedented inhibitory activity on human farnesyltransferase.
    Dumea C; Belei D; Ghinet A; Dubois J; Farce A; Bîcu E
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5777-5781. PubMed ID: 25453818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization.
    Langdon SR; Ertl P; Brown N
    Mol Inform; 2010 May; 29(5):366-85. PubMed ID: 27463193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergies of virtual screening approaches.
    Muegge I
    Mini Rev Med Chem; 2008 Aug; 8(9):927-33. PubMed ID: 18691150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A validation study on the practical use of automated de novo design.
    Stahl M; Todorov NP; James T; Mauser H; Boehm HJ; Dean PM
    J Comput Aided Mol Des; 2002 Jul; 16(7):459-78. PubMed ID: 12510880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.
    DeGraw AJ; Keiser MJ; Ochocki JD; Shoichet BK; Distefano MD
    J Med Chem; 2010 Mar; 53(6):2464-71. PubMed ID: 20180535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico based structural analysis of some piperidine analogs as farnesyltransferase inhibitors.
    Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA
    Med Chem; 2012 Sep; 8(5):853-64. PubMed ID: 22741784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of farnesyltransferase: a rational approach to treat cancer?
    Puntambekar DS; Giridhar R; Yadav MR
    J Enzyme Inhib Med Chem; 2007 Apr; 22(2):127-40. PubMed ID: 17518338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Competitive Workflow: novel software architecture for automating drug design.
    Cartmell J; Krstajic D; Leahy DE
    Curr Opin Drug Discov Devel; 2007 May; 10(3):347-52. PubMed ID: 17554862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
    Floresta G; Apirakkan O; Rescifina A; Abbate V
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.
    Liu Q; Masek B; Smith K; Smith J
    J Med Chem; 2007 Nov; 50(22):5392-402. PubMed ID: 17918924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.